FilingReader Intelligence
Cohance Lifesciences receives FDA inspection observations
August 13, 2025 at 05:49 PM UTC•By FilingReader AI
The FDA conducted a Good Manufacturing Practices inspection at Cohance Lifesciences' manufacturing facility in Hyderabad from August 4-12, 2025.
The company received a Form 483 with six predominantly procedural observations and is preparing a comprehensive response.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:SUVENPHAR•Bombay Stock Exchange
News Alerts
Get instant email alerts when SUVEN PHARMACEUTICALS publishes news
Free account required • Unsubscribe anytime